Greater Bay Area Homeland Development, an investment business, led a $105m Series C funding round in Elpiscience, a clinical stage biopharmaceutical company focusing on cancer immunotherapy. Additional investors included Cormorant Asset Management, Maison Capital, Superstring Capital, Pluto Connection, Unifortune Fund, Lilly Asia Ventures, Hillhouse Capital Group, CDH Investments, Dyee Capital and Oriza. “We are thrilled to have the continued support and endorsement from the top tier investors. It’s been a remarkable 3.5 years. Elpiscience is determined to become a innovation leader in developing the next generation of cancer immunotherapies. We are committed to bringing at least one world-class molecule into the clinic each year to benefit cancer patients globally," Darren Ji, Elpiscience Chairman and CEO.